Morningstar

Evotec SE EVT

Morningstar Rating
Unlock
Stock XETR Rating as of
€6.14 +0.15 (2.50%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive

Rachel Elfman,

Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on collaboration with clients. The firm offers services across a variety of therapeutic areas and serves a diverse client base of large and midsize pharmaceutical and biotechnology companies. Following a recent period of investment that has weighed on returns, Evotec appears well positioned to mature and stabilize its business as its strategic growth initiatives materialize.

Read Full Report

Price vs Fair Value

View History
EVT is trading at a 556% premium.
Price
€6.14
Fair Value
€1.10
Uncertainty
High
1-Star Price
€67.39
5-Star Price
€6.10
Economic Moat
Rqxx
Capital Allocation
Wvsfdnrz

Bulls Say, Bears Say

Bulls

Evotec’s focus on building out its biologics manufacturing capacity makes it well positioned to capture heightened demand for biologics by biopharma companies.

Bears

Competitive market dynamics remain fierce, weighing on Evotec’s organic growth in the Shared R&D segment and putting pricing pressure on the firm’s more commoditized services.

Show More

News

View All

Trading Information

Previous Close Price
€5.99
Day Range
€5.99–6.23
52-Week Range
€5.06–21.69
Bid/Ask
€0.00 / €6.14
Market Cap
€1.09 Bil
Volume/Avg
701,624 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
1.38
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
5,022
Website
https://www.evotec.com

Competitors

Valuation

View More
Metric
EVT
LONN
SFZN
Price/Earnings (Normalized)
 —32.5834.88
Price/Book Value
 1.084.055.70
Price/Sales
 1.385.673.83
Price/Cash Flow
 —28.5225.03
Price/Earnings
EVT
LONN
SFZN

Financial Strength

Metric
EVT
LONN
SFZN
Quick Ratio
 1.591.381.19
Current Ratio
 1.832.042.70
Interest Coverage
 −14.736.8817.61
Quick Ratio
EVT
LONN
SFZN

Profitability

Metric
EVT
LONN
SFZN
Return on Assets (Normalized)
 −3.43%5.18%7.69%
Return on Equity (Normalized)
 −6.80%9.32%18.01%
Return on Invested Capital (Normalized)
 −4.13%7.38%11.28%
Return on Assets
EVT
LONN
SFZN

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
RbphgwjhzkSbmxp$86.1 Bil
 Merck KGaA ADR
MKKGY
KyqrbydrwNnzkrd$74.3 Bil
 Haleon PLC ADR
HLN
NvmrnfmypXbb$45.9 Bil
 Viatris Inc
VTRS
HczfnhdgSwd$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
WlltlnlPtpm$13.2 Bil
 Catalent Inc
CTLT
WbxgvlgVzlsjlp$11.0 Bil
 Prestige Consumer Healthcare Inc
PBH
HwyyqwqsFmlynh$3.4 Bil
 Perrigo Co PLC
PRGO
NysshzjYzwn$3.4 Bil
 Green Thumb Industries Inc
GTBIF
MyzlsbtrcwYjg$2.4 Bil
 Curaleaf Holdings Inc
CURLF
XldnywznLrvf$2.2 Bil

Sponsor Center